StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Equities researchers at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of NASDAQ BLPH opened at $0.04 on Monday. The business has a 50 day simple moving average of $0.04 and a 200 day simple moving average of $0.05. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.41. The stock has a market cap of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.